Systemic Availability of Inhaled Budesonide and Fluticasone Propionate
- 51 Downloads
Inhaled corticosteroids are now recommended for the majority of patients with asthma. Although their therapeutic ratio is superior to that of oral corticosteroids, their long term use is associated with several potentially important adverse effects. A number of studies have compared the efficacy and/or systemic activity of the currently available inhaled corticosteroids, but the results of many of these studies have been conflicting. Although there are a number of factors that may explain these conflicting results, there is evidence that the type of individuals being studied is important. Extrapolation of the findings from healthy individuals to patients with asthma appears to be misleading because the systemic effects of some, but not all, inhaled corticosteroids are greater in healthy individuals than in patients with asthma.
KeywordsAsthma Budesonide Fluticasone Propionate Beclomethasone Dipropionate Mild Asthma
Dr Harrison has attended and spoken at meetings at the request of AstraZeneca and Glaxo SmithKline pharmaceuticals.
- 14.Grahnén A, Jansson B, Brundin RM, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. J Clin Pharmacol 1997; 52: 261–7Google Scholar
- 17.Harrison TW, Tattersfield AE. Systemic bioavailability of fluticasone propionate and budesonide given by dry powder inhalers in healthy and asthmatic subjects [abstract]. Am J Respir Crit Care Med 2001; 163: A517Google Scholar
- 18.Lofdahl L, Thorsson L. Systemic availability of inhaled fluticasone propionate and budesonide was the same in asthmatic subjects and healthy subjects [abstract]. Am J Respir Crit Care Med 1999; 159: A118Google Scholar
- 21.Hogger P, Rawert L, Rohdewald P. Dissolution tissue binding and kinetics of receptor binding of inhaled glucocorticoids [abstract]. Eur Respir J 1993; 6: 584SGoogle Scholar